Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$27.5 0.9  3.5%

Last Trade - 14/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £705.5m
Enterprise Value £482.0m
Revenue £n/a
Position in Universe 2850th / 6846

Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

Wed 10th March, 2021 9:58pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210310:nGNXb4pQ0c&default-theme=true


CAMBRIDGE, Mass. and NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Black
Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine
company pioneering the discovery and development of small molecule,
tumor-agnostic therapies, today announced that pre-clinical data on BDTX-189
and BDTX-1535 will be presented as late-breaking poster presentations at the
American Association for Cancer Research (AACR) Virtual Annual Meeting, taking
place April 10-15, 2021.

Presentation details are as follows:

Title: Prospective pre-clinical modeling to estimate clinical pharmacokinetics
and doses of BDTX-189, an inhibitor of allosteric ErbB mutations in advanced
solid malignancies 
Session Type: E-Poster Session 
Session Category: Experimental and Molecular Therapeutics
Session Title: Pharmacology, Pharmacogenetics, and Pharmacogenomics
Date and Time: Saturday, April 10, 8:30 AM ET
Abstract Number: LB127

Title: CNS penetrant, irreversible inhibitors potently inhibit the family of
allosteric oncogenic EGFR mutants expressed in GBM and demonstrate efficacy in
patient-derived xenograft models 
Session Type: E-Poster Session 
Session Category: Experimental and Molecular Therapeutics
Session Title: Tyrosine Kinase and Phosphatase Inhibitors 
Date and Time: Saturday, April 10, 8:30 AM ET
Abstract Number: LB140

Full abstracts will be published online at 12:01 AM ET on April 9, 2021 on the
AACR website at www.aacr.org. Both presentations will also be available online
on the Company’s website at
https://www.blackdiamondtherapeutics.com/technology/presentations-publications/.

About BDTX-189
BDTX-189 is an orally available, irreversible small molecule inhibitor that
blocks the function of an undrugged family of oncogenic proteins defined by
driver mutations across a range of tumor types, and which affect both of the
epidermal growth factor receptor (EGFR) and the tyrosine-protein kinase,
ErbB-2, or human epidermal growth factor receptor 2 (HER2). These mutations
include extracellular domain allosteric mutations of HER2, as well as EGFR and
HER2 kinase domain exon 20 insertions, and additional activating oncogenic
drivers of ErbB. The ErbB receptors are a group of receptor tyrosine kinases
involved in key cellular functions, including cell growth and survival.
BDTX-189 is also designed to spare normal, or wild type EGFR, which we believe
will improve upon the toxicity profiles of current ErbB kinase inhibitors.

Currently, there are no medicines approved by the U.S. Food and Drug
Administration to target all of these oncogenic mutations with a single
therapy.

About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering
the discovery of small molecule, tumor-agnostic therapies. Black Diamond
targets undrugged mutations in patients with genetically defined cancers.
Black Diamond is built upon a deep understanding of cancer genetics, protein
structure and function, and medicinal chemistry. The Company’s proprietary
technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is
designed to allow Black Diamond to analyze population-level genetic sequencing
data to identify oncogenic mutations that promote cancer across tumor types,
group these mutations into families, and develop a single small molecule
therapy in a tumor-agnostic manner that targets a specific family of
mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth
Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began
building the MAP platform and chemistry discovery engine. For more
information, please visit www.blackdiamondtherapeutics.com.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com

(https://www.globenewswire.com/NewsRoom/AttachmentNg/b8da4d92-789b-4f0a-a1e2-2739af370155)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.